DECIBEL THERAPEUTICS INC (DBTX) Stock Price, Quote, News and Overview
NASDAQ:DBTX - Nasdaq - US24343R1068 - Common Stock - Currency: USD
DBTX Quote, Performance and Key Statistics
4.91
-0.04 (-0.81%)
The current stock price of DBTX is 4.91 USD. In the past month the price decreased by -4.1%. In the past year, price increased by 28.53%.
DBTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About DBTX
Company Profile
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Company Info
DECIBEL THERAPEUTICS INC
1325 Boylston Street, Suite 500
Boston MASSACHUSETTS 02215 US
CEO: Laurence Reid
Employees: 68
Company Website: https://www.decibeltx.com/
Phone: 16173708701.0
DECIBEL THERAPEUTICS INC / DBTX FAQ
What is the stock price of DECIBEL THERAPEUTICS INC today?
The current stock price of DBTX is 4.91 USD. The price decreased by -0.81% in the last trading session.
What is the ticker symbol for DECIBEL THERAPEUTICS INC stock?
The exchange symbol of DECIBEL THERAPEUTICS INC is DBTX and it is listed on the Nasdaq exchange.
On which exchange is DBTX stock listed?
DBTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DECIBEL THERAPEUTICS INC stock?
10 analysts have analysed DBTX and the average price target is 7.78 USD. This implies a price increase of 58.4% is expected in the next year compared to the current price of 4.91. Check the DECIBEL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DECIBEL THERAPEUTICS INC worth?
DECIBEL THERAPEUTICS INC (DBTX) has a market capitalization of 123.39M USD. This makes DBTX a Micro Cap stock.
How many employees does DECIBEL THERAPEUTICS INC have?
DECIBEL THERAPEUTICS INC (DBTX) currently has 68 employees.
What are the support and resistance levels for DECIBEL THERAPEUTICS INC (DBTX) stock?
DECIBEL THERAPEUTICS INC (DBTX) has a support level at 4.9 and a resistance level at 5.05. Check the full technical report for a detailed analysis of DBTX support and resistance levels.
Is DECIBEL THERAPEUTICS INC (DBTX) expected to grow?
The Revenue of DECIBEL THERAPEUTICS INC (DBTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the DBTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DECIBEL THERAPEUTICS INC (DBTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DBTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DBTX, evaluating the profitability, health, valuation and growth aspects
- DECIBEL THERAPEUTICS INC (DBTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DECIBEL THERAPEUTICS INC (DBTX) Sales and EPS estimates to see what analysts future expectations are.
- DECIBEL THERAPEUTICS INC (DBTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DECIBEL THERAPEUTICS INC (DBTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- DECIBEL THERAPEUTICS INC (DBTX) Stock Chart to make your own analysis
- DECIBEL THERAPEUTICS INC (DBTX) Latest news and press-releases to stay up to date.
Does DECIBEL THERAPEUTICS INC (DBTX) stock pay dividends?
DBTX does not pay a dividend.
When does DECIBEL THERAPEUTICS INC (DBTX) report earnings?
DECIBEL THERAPEUTICS INC (DBTX) will report earnings on 2023-11-07, after the market close.
What is the Price/Earnings (PE) ratio of DECIBEL THERAPEUTICS INC (DBTX)?
DECIBEL THERAPEUTICS INC (DBTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.53).
DBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DBTX. When comparing the yearly performance of all stocks, DBTX is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
DBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DBTX. DBTX may be in some trouble as it scores bad on both profitability and health.
DBTX Financial Highlights
Over the last trailing twelve months DBTX reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -9.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DBTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to DBTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -15% and a revenue growth -100% for DBTX